Plain-English translation of NCT06963827 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help people with IgA nephropathy — a kidney disease where the immune system causes inflammation and damage inside the kidneys. About 347 adults will participate: most will randomly receive either the medication or a placebo (a fake injection) for about 6 months, then be monitored for another year and a half. The study aims to see if this treatment reduces protein in the urine and helps protect kidney function over time.
IgA nephropathy is a serious kidney disease that can get worse over time and lead to kidney failure. Current treatments help, but many patients still lose kidney function. This medication targets a specific part of the immune system in a new way, and researchers want to find out if it can better protect the kidneys compared to standard care alone.
You likely qualify if…
You likely don't qualify if…
If you join the main study, you'll be randomly assigned to receive either the medication or a placebo as injections under the skin every week for about 6 months. After that, you'll stop receiving injections but continue visiting the clinic monthly for about another year and a half so doctors can monitor your kidney function and protein levels. You'll have several clinic visits throughout the 2-year study to have blood and urine tests done.
AI-generated summary from trial data · Oct 2, 2026 · Not medical advice
United States